CY1110437T1 - Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c - Google Patents

Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c

Info

Publication number
CY1110437T1
CY1110437T1 CY20081101328T CY081101328T CY1110437T1 CY 1110437 T1 CY1110437 T1 CY 1110437T1 CY 20081101328 T CY20081101328 T CY 20081101328T CY 081101328 T CY081101328 T CY 081101328T CY 1110437 T1 CY1110437 T1 CY 1110437T1
Authority
CY
Cyprus
Prior art keywords
treatment
usitis
kastanospermin
products
esters
Prior art date
Application number
CY20081101328T
Other languages
English (en)
Inventor
Albert Stanley Tyms
Debra Lynn Taylor
Original Assignee
Virogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogen Ltd filed Critical Virogen Ltd
Publication of CY1110437T1 publication Critical patent/CY1110437T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Χρήση ορισμένων εστέρων καστανοσπερμίνης στην θεραπεία ασθενειών που προκαλούνται από ιούς ηπατίτιδας C, ιδιαίτερα στην θεραπεία της ασθένειας που προκαλείται από τον ιό της ηπατίτιδας C (HCV) και συνθέσεις που περιέχουν τους εν λόγω εστέρες σε συνδυασμό με βοηθητικούς θεραπευτικούς παράγοντες.
CY20081101328T 2001-05-03 2008-11-19 Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c CY1110437T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110832.3A GB0110832D0 (en) 2001-05-03 2001-05-03 Antiviral compounds
EP02742947A EP1387681B1 (en) 2001-05-03 2002-05-02 Use of castanospermine derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
CY1110437T1 true CY1110437T1 (el) 2015-04-29

Family

ID=9913938

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101328T CY1110437T1 (el) 2001-05-03 2008-11-19 Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c

Country Status (20)

Country Link
US (1) US7601735B2 (el)
EP (1) EP1387681B1 (el)
JP (2) JP2004527566A (el)
KR (1) KR100660241B1 (el)
CN (1) CN100428936C (el)
AT (1) ATE405261T1 (el)
AU (1) AU2002341155B2 (el)
CA (1) CA2445271A1 (el)
CY (1) CY1110437T1 (el)
DE (1) DE60228436D1 (el)
DK (1) DK1387681T3 (el)
ES (1) ES2312587T3 (el)
GB (1) GB0110832D0 (el)
HK (1) HK1068538A1 (el)
IL (2) IL158558A0 (el)
NO (1) NO326292B1 (el)
NZ (1) NZ529448A (el)
PT (1) PT1387681E (el)
WO (1) WO2002089780A2 (el)
ZA (1) ZA200308483B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2576425A1 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
EP1802327A4 (en) * 2004-10-06 2009-07-15 Migenix Inc COMBINED ANTIVIRAL COMPOSITIONS WITH CASTANOSPERMIN AND METHOD OF USE
MX2007009561A (es) * 2005-02-09 2008-01-14 Migenix Inc Composiciones y metodos para tratar o evitar infecciones de flaviviridae.
JP2007297289A (ja) * 2006-04-27 2007-11-15 Kitasato Gakuen 抗ウイルス剤
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
KR101314166B1 (ko) * 2011-06-16 2013-10-04 건국대학교 산학협력단 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
AU2014228035B2 (en) 2013-03-15 2018-12-06 60 Degrees Pharmaceuticals Llc Novel dosing regimens of celgosivir for the treatment of dengue
PE20160501A1 (es) * 2013-09-27 2016-05-14 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
US10046005B2 (en) * 2014-02-07 2018-08-14 Shaker A. Mousa Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016368580B2 (en) * 2015-12-11 2021-08-19 60° Pharmaceuticals Llc Novel dosing regimens of celgosivir for the prevention of dengue
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AU2017242893A1 (en) 2016-03-31 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
UA125407C2 (uk) 2017-05-22 2022-03-02 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
WO2021132626A1 (ja) * 2019-12-27 2021-07-01 国立大学法人北海道大学 豚熱の治療及び／又は予防剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1315276C (en) 1987-07-02 1993-03-30 Paul S. Liu Castanospermine esters and glycosides
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4970317A (en) * 1989-08-08 1990-11-13 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine esters
US5093501A (en) * 1990-03-12 1992-03-03 Merrell Dow Pharmaceuticals Inc. Intermediates in a process for the preparation of castanospermine
US5066807A (en) * 1990-03-12 1991-11-19 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine
GB9027433D0 (en) * 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US5959111A (en) * 1997-05-22 1999-09-28 Hoechst Marion Roussel, Inc. Process for preparing 6-0-monoesters of castanospermine
EP1037636A4 (en) * 1997-12-11 2004-08-18 Univ Oxford INHIBITATION OF MEMBRANE-TIED VIRAL REPLICATION
WO2001054692A1 (en) * 2000-01-28 2001-08-02 Synergy Pharmaceuticals, Inc. Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Also Published As

Publication number Publication date
ZA200308483B (en) 2005-10-26
EP1387681B1 (en) 2008-08-20
JP2004527566A (ja) 2004-09-09
DK1387681T3 (da) 2009-01-05
ATE405261T1 (de) 2008-09-15
KR20040007527A (ko) 2004-01-24
EP1387681A2 (en) 2004-02-11
DE60228436D1 (de) 2008-10-02
WO2002089780A3 (en) 2003-03-06
WO2002089780A2 (en) 2002-11-14
NZ529448A (en) 2005-11-25
CN100428936C (zh) 2008-10-29
AU2002341155B2 (en) 2007-10-18
IL158558A (en) 2011-09-27
PT1387681E (pt) 2008-12-02
KR100660241B1 (ko) 2006-12-20
ES2312587T3 (es) 2009-03-01
CA2445271A1 (en) 2002-11-14
JP4406383B2 (ja) 2010-01-27
HK1068538A1 (en) 2005-04-29
NO20034878L (no) 2003-12-22
NO20034878D0 (no) 2003-10-31
IL158558A0 (en) 2004-05-12
US7601735B2 (en) 2009-10-13
GB0110832D0 (en) 2001-06-27
NO326292B1 (no) 2008-11-03
US20040147549A1 (en) 2004-07-29
JP2005290015A (ja) 2005-10-20
CN1516582A (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
WO2006130627A3 (en) Methods for treating hepatitis c
AU2002360592A8 (en) Inhibitors of hepatitis c virus
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
ATE269321T1 (de) Arzneimittel gegen virale erkrankungen
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE381323T1 (de) Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol
EA200700718A1 (ru) Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
DOP2003000641A (es) Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
ATE373644T1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
WO2004062575A3 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses
MXPA05007901A (es) Terapia de combinacion para hcv.